A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension
Phase of Trial: Phase I
Latest Information Update: 11 Jun 2015
Price : $35 *
At a glance
- Drugs Bimatoprost (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors ForSight VISION5
- 11 Jun 2015 According to a ForSight VISION5 media release, data from this trial were presented at the World Glaucoma Congress.
- 16 Dec 2014 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 08 Dec 2013 New trial record